Cevidoplenib
Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively[1][2][3].
Product Specifications
CAS Number
1703788-21-9
Product Name Alternative
SKI-O-703
UNSPSC
12352005
Target
Syk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cevidoplenib.html
Purity
99.58
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1CC1)C2=CN(C)C3=C2C=C(NC4=NC=CC(N5N=C(C)C(CN6OC[C@@H](O)C6)=C5)=N4)C=C3
Molecular Formula
C25H27N7O3
Molecular Weight
473.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Psmd4 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)
